Login to Your Account



Genzyme's 2004: Strong Sales, Growth Provided 'Stellar' Year

By Karen Pihl-Carey


Thursday, January 13, 2005
With increased revenues of 23 percent in the fourth quarter, Genzyme Corp. exceeded analyst expectations, ending the year with two major acquisitions under its belt and an FDA approval for Clolar. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription